Auvelity

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor all patients closely for clinical worsening and emergence of suicidal thoughts and behaviors (esp. during the initial few months and at times of dosage changes). Consider alternative regimen including discontinuing treatment if depression worsens or if suicidal thoughts/behaviors occur. Increased risk of seizure with severe head injury, arteriovenous malformation, CNS tumor or CNS infection, severe stroke, metabolic disorders. Discontinue and do not restart treatment if seizure occurs. Risk of dose-related neuropsychiatric reactions (eg, delusions, hallucinations, psychosis, concentration disturbance, paranoia, confusion). Angle-closure glaucoma. Avoid use in those with untreated anatomically narrow angles. Monitor BP prior to initiation and periodically during treatment. Screen for a history of bipolar disorder, mania, or hypomania. Screen for other medications containing bupropion or dextromethorphan. Severe renal (eGFR 15–29mL/min/1.73m²) or hepatic (Child-Pugh C) impairment: not recommended. Embryo-fetal toxicity. Use alternative treatment for females who are planning to become pregnant. Pregnancy: not recommended; discontinue if occurs during treatment. Nursing mothers: not recommended (during and for 5 days after the last dose).